NTI 1.45% 7.0¢ neurotech international limited

No results seem to be available to you or me. Only to the people...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,116 Posts.
    lightbulb Created with Sketch. 207
    No results seem to be available to you or me. Only to the people who were at the conference. As they have been for several days. The announcement is price sensitive, the market reacted accordingly. There is problem number one for the company; timely disclosure.

    Problem number two. The ASX has a code for life sciences companies reporting trial results. There is a proper format to be followed. This remains the case even when preliminary results are reported (see page 11).

    The company has produced a completely non-complying results announcement. There are very good reasons for each of the reporting elements in the code. Without these elements being present the veracity of trial results cannot be properly assessed.
    http://www.asx.com.au/documents/res...e_for_Reporting_by_Life_Science_Companies.pdf

    On CE Mark and TGA approval.

    CE mark approval doesn’t say the device actually works. It simply says that the device is made consistently to standards and that you can trace where everything came from.

    TGA approval – a low risk device gets virtually no scrutiny of efficacy evidence. There are hundreds of these devices TGA listed that are useless.
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
7.0¢
Change
0.001(1.45%)
Mkt cap ! $64.55M
Open High Low Value Volume
7.1¢ 7.1¢ 7.0¢ $16.67K 237.0K

Buyers (Bids)

No. Vol. Price($)
3 75250 6.9¢
 

Sellers (Offers)

Price($) Vol. No.
7.0¢ 23082 1
View Market Depth
Last trade - 14.13pm 28/11/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.